

SCIINV Biosciences and Microbira to launch cutting-edge digital diagnostics for combatting superbugs in India

18 June 2025 | News

To serve as scalable solutions for global AMR containment

In a decisive step to tackle one of the world's most pressing public health threats, SCIINV Biosciences, a Hyderabad-based biotech startup incubated at ASPIRE BioNEST, University of Hyderabad (UoH), has announced a strategic partnership with Microbira Limited, a UK-based biotechnology firm. The collaboration aims to develop and deploy next-generation digital diagnostic solutions to strengthen India's fight against antimicrobial resistance (AMR).

At the heart of this Indo-UK alliance lies a shared commitment to revolutionize microbial diagnostics by building a rapid, accurate, and affordable detection platform. The joint innovation AMRx and MAAP IR is focused on early and precise pathogen identification, thereby minimizing the misuse of broad-spectrum antibiotics—a major driver of AMR, particularly in high-disease-burden regions like India.

Prof. Reddanna Pallu, Senior Professor (Retd.), School of Life Sciences, University of Hyderabad, underscored the clinical importance of this initiative, "This initiative is a crucial step in curbing inappropriate antibiotic use through timely pathogen detection. Such targeted interventions are fundamental in our fight against drug resistance."

Marianne Ismail, CEO of Microbira Ltd, emphasised the global relevance of the partnership, "This alliance underscores our shared commitment to tackling one of the most important global health challenges. It's a meaningful example of innovation-driven collaboration between the UK and India."